NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Valion Bio, Inc. (VBIO) Stock Analysis

Valion Bio, Inc. (VBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VBIO

$1.12

−$0.07 (−5.88%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VBIO with… →

VBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.20
Previous Close
$1.19
Day's Range
1.10–1.20
52-Week Range
1.05–73.23
Volume
194.55K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$2.18M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−177.91
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.88M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.95M
1-Year Return
−98.48%
Dividend and dates
Avg Volume
1.69M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VBIO closed at $1.12, −98.48% over 1 year.

Valion Bio, Inc. (VBIO) has a market capitalization of $2.18M.

In fiscal 2025, VBIO reported revenue of $0.00.

VBIO Stock Return by Calendar Year

Valion Bio, Inc. (VBIO) return since Nov 2021: what $10,000 became

1 year
$10,000 $152
−98.48%
5 years
$10,000 $0.05
−99.999%

If you had invested $10,000 in Valion Bio, Inc. (VBIO) at the close on November 11, 2021, the earliest close on record here, it would have been worth $0.05 at the close on October 21, 2026: −99.999% in total, −91.27% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−96.91%
2025−75.35%
2024−80.78%
2023−97.19%
2022−83.51%
2021 (partial year)−25.24%

As of October 21, 2026.

VBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.88M—
2024$0.00−$5.66M—
2023$1.18M−$8.24M−701.0%
2022$1.84M−$10.10M−548.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$7.90M−$8.88M—
2024$0.00$2.00K−$4.48M−$5.66M—
2023$1.18M$287.00K−$8.25M−$8.24M−701.0%
2022$1.84M$299.00K−$10.10M−$10.10M−548.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Valion Bio, Inc. (VBIO) at $2.18M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 52 employees.

The most recent close on file for VBIO is $1.12, dated October 21, 2026. That is −$0.07 (−5.88%) against the previous close. The 52-week range on file runs from $1.05 to $73.23. The latest close sits 7.18% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.88M. Earnings per share on a trailing basis come to −177.91.

Across the 4 fiscal years on file, revenue moves from $1.84M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.8. Annualized volatility over the trailing 4 years is 190.4%. Over the trailing twelve months the total return is −98.48%. Measured over 5 years, that is −91.27% a year compounded.

Growth & Income

The record shows no dividend for VBIO.

The strongest complete calendar year on file is 2025 at −75.35%; the weakest is 2023 at −97.19%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the total return is −96.91%.

Peer Comparison

Valion Bio, Inc. (VBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Valion Bio, Inc. VBIO $2.18M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Valion Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Visit website →